Medication Quick Facts
📋Overview
Glyxambi is a combination therapy that contains the active ingredients empagliflozin and linagliptin. These components belong to different classes of medications known as sodium-glucose co-transporter 2 (SGLT2) inhibitors and dipeptidyl peptidase-4 (DPP-4) inhibitors.
The medication works through multiple pathways to help the body regulate glucose levels. By combining these two classes of medicine, the therapy provides a multi-faceted approach to glycemic control.
🛡️ Educational information only
This content is provided for general health education and awareness and is based on publicly available medical information. It is not intended to replace professional medical advice, diagnosis, or treatment, and should not be used to make healthcare decisions. Always seek the guidance of a qualified healthcare professional regarding any medical condition, medication, supplement, or procedure.
Found an Error?
Help us keep this information accurate. If you notice any incorrect details, please submit a correction request.
